Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewN-(4-Bromobenzyl)-5-methoxytryptamine oxalate
Discontinued Product
N-(4-Bromobenzyl)-5-methoxytryptamine oxalate (Cat. No. 0755) has been withdrawn from sale for commercial reasons.
Description: 5-HT2A ligand
Biological Activity
Very potent and selective ligand at 5-HT2A receptors (Ki = 0.1 nM).
Technical Data
| M. Wt | 449.3 |
| Storage | Desiccate at +4°C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References
References are publications that support the biological activity of the product.
Glennon et al (1994) Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. J.Med.Chem. 37 1929 PMID: 8027974
View Related Products by Target
View Related Products by Product Action
Keywords: N-(4-Bromobenzyl)-5-methoxytryptamine oxalate, N-(4-Bromobenzyl)-5-methoxytryptamine oxalate supplier, 5-HT2A, Receptors, 0755, Tocris Bioscience
Citations for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate
Citations are publications that use Tocris products.
Currently there are no citations for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate.
Reviews for N-(4-Bromobenzyl)-5-methoxytryptamine oxalate
There are currently no reviews for this product. Be the first to review N-(4-Bromobenzyl)-5-methoxytryptamine oxalate and earn rewards!
Have you used N-(4-Bromobenzyl)-5-methoxytryptamine oxalate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cardiovascular Research Product Guide
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Hypertension
- Thrombosis and Hemostasis
- Atherosclerosis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Arrhythmias
- Heart Failure
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Cardiovascular Poster
Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.